Showing 6141-6150 of 8709 results for "".
- ISDIN Sunscreen Survey: Just 37% of the US Population Protects Themselves from the Sun on a Daily Basishttps://practicaldermatology.com/news/isdin-sunscreen-survey-just-37-of-the-us-population-protects-themselves-from-the-sun-on-a-daily-basis/2460505/While half of the US population is aware of the importance of sun protection and state they use sun protection during sun exposure, only 37 percent are using it on a daily basis, according to new survey from ISDIN. In the s
- InMode Introduces the Morpheus8 Platform and the Morpheus8 Body Fractional Technologyhttps://practicaldermatology.com/news/inmode-introduces-the-morpheus8-platform-and-the-morpheus8-body-fractional-technology/2460501/InMode Ltd. is introducing the Morpheus8 Body handpiece and Morpheus8 Platform. Morpheus8 Body is a full-body fractional technology that delivers RF energy up to a thermal depth of 8mm (7mm pin depth + an additional 1mm thermal profile), with its
- Laseroptek Introduces Pallas UVB Laser in UShttps://practicaldermatology.com/news/laseroptek-introduces-pallas-uvb-laser-in-us/2460499/South Korea-based Laseroptek Co., Ltd. is launching the Pallas Solid-State 311nm UVB laser for the treatment of vitiligo, psoriasis, atopic dermatitis and leukoderma in the United States. Pallas allows the choice of either 308 or 311 nanomet
- Merz Aesthetics Rolls Out “Confidence to Be” Branding Platform and Other Changeshttps://practicaldermatology.com/news/merz-aesthetics-rolls-outconfidence-to-be-branding-platform-and-other-changes/2460497/Merz Aesthetics is launching its new “confidence to be” branding platform following the conclusion of the company’s reorganization. Merz is now three independently operating businesses: medical aesthetics, therapeutics and consumer care. “The new brand
- Membership Has Its Privileges: RealSelf Rolls Out RealSelf Insider Programhttps://practicaldermatology.com/news/membership-has-its-privileges-realself-rolls-out-realself-insider-program/2460496/RealSelf is introducing RealSelf INSIDER, a new membership program that offers cash rewards for cosmetic treatments as well as exclusive perks, including free virtual consultatio
- SoftWave Tissue Regeneration Technologies Takes On Cellulitehttps://practicaldermatology.com/news/softwave-tissue-regeneration-technologies-takes-on-cellulite/2460494/SoftWave Tissue Regeneration Technologies plans to start a 60-patient study to evaluate the safety and efficacy of the DermaGold device for the temporary improvement in the appearance of cellulite. The company has a pa
- This Is Why Sarecycline Is So Effective Against Acnehttps://practicaldermatology.com/news/this-is-why-sarecycline-is-so-effective-against-acne/2460488/Researchers at Yale and the University of Illinois-Chicago have discovered how Sarecycline’s unique chemical structure makes it so effective against acne. Unlike other tetracycline drugs, sarecycline binds to messenger RNA (mRNA) in bacterial ribosomes. Sarecycline and other
- Rihanna Introduces Fenty Skinhttps://practicaldermatology.com/news/rihanna-introduces-fenty-skin/2460487/Rihanna, in partnership with Kendo Brands, is rolling out Fenty Skin. After years of feeling overwhelmed by all the skincare choices and a bad experience with a product that discolored her skin as a teen, Rihanna dreamed of creating a line that was easy and effective. Now, she'
- Genentech’s Tecentriq plus Cotellic and Zelboraf Approved for Advanced Melanomahttps://practicaldermatology.com/news/genentechs-tecentriq-plus-cotellic-and-zelboraf-approved-for-advanced-melanoma/2460483/Tecentriq (atezolizumab) is now approved in combination with Cotellic (cobimetinib) and Zelboraf(vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety profile observed in the Tecentriq combination was consistent with the known safety profil
- Stelara Approved for PsO in Kids Ages 6-11https://practicaldermatology.com/news/stelara-approved-for-pso-in-kids-ages-6-11/2460482/Stelara® (ustekinumab) is now approved for pediatric patients (6-11 years of age) with moderate to severe plaque psoriasis (PsO). Stelara, from The Janssen Pharmaceutical Companies of Johnson & Johnson, targets both interleukin (IL)-12 and IL-23